GlobeImmune Announces Pricing of Initial Public Offering
LOUISVILLE, Colo., July 1, 2014 (GLOBE NEWSWIRE) -- GlobeImmune, Inc. (GBIM), today announced the pricing of its initial public offering of 1,500,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to GlobeImmune from the initial public offering are expected to be $15,000,000, before underwriting discounts and commissions and other offering expenses. In addition, GlobeImmune has granted the underwriter a 45-day option to purchase up to 225,000 additional shares of common stock from GlobeImmune to cover over-allotments, if any. GlobeImmune’s common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading tomorrow under the symbol “GBIM.”
The offering is expected to close on July 8, 2014, subject to customary closing conditions.
Aegis Capital Corp. is acting as sole book-running manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 1, 2014. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, via telephone: 212-813-1010, or via e-mail: prospectus@aegiscap.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About GlobeImmune
GlobeImmune is a biopharmaceutical company focused on developing products for the treatment of infectious disease and oncology based on its proprietary Tarmogen platform. Tarmogens are believed to activate the immune system by stimulating cellular immunity, known as T cell immunity, in contrast to traditional vaccines that predominately stimulate antibody production. To date, Tarmogen product candidates have been generally well tolerated in clinical trials for multiple disease indications and are efficient to manufacture. In May 2009, the company entered into a collaboration agreement with Celgene Corporation focused on the discovery, development and commercialization of product candidates for the treatment of cancer. In October 2011, the company entered into a worldwide, strategic collaboration with Gilead Sciences, Inc., to develop Tarmogens for the treatment of chronic hepatitis B infection. For additional information, please visit the company’s website at www.globeimmune.com.
Contact:
GLOBEIMMUNE CONTACT:
Timothy C. Rodell, M.D.
Chief Executive Officer and President
T: 303-625-2820
information@globeimmune.com
INVESTOR CONTACT:
Susan Noonan
S.A. Noonan Communications, LLC
T: 212-966-3650
susan@sanoonan.com
GLOBEIMMUNE MEDIA CONTACTS:
Lena Evans or Tony Russo, Ph.D.
Russo Partners LLC
T: 212-845-4262 or 212-845-4251
lena.evans@russopartnersllc.com
tony.russo@russopartnersllc.com
Help employers find you! Check out all the jobs and post your resume.
